Rigel Pharmaceutical (RIGL) 3.40 $RIGL
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), MYL: 39.97 (-1.95), AMGN: 169.77 (-0.36), ARIA: 10.12 (-0.07), RIGL: 3.40 (-0.05), REGN: 388.64 (-4.76)
Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:16AM CDT
Rigel (RIGL) announced positive data from a phase III study on fostamatinib for the treatment of adult chronic/persistent ITP.
ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33), RIGL: 3.40 (-0.05)
Market Movers & Headline Makers On Tuesday
PR Newswire - Tue Aug 30, 10:17AM CDT
TechStockInsider.com Briefing: Despite the continued market confusion, stocks have remained in the center stage on Tuesday. The markets have been relatively quiet during these last few weeks of the summer and it has many traders confused. As one CNBC article states, "Stocks are just doing their own thing, which is why they've been so confusing for traders over the last few weeks." Despite this case, many companies are gaining attention for major milestones being hit prior to the start of the school season. Companies like Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), Life Clips, Inc. (OTCQB: LCLP), Skyline Medical Inc. (NASDAQ: SKLN), and Progressive Care, Inc. (OTC: RXMD) have all gained attention in the markets for their recent announcements.
SKLN: 0.18 (+0.02), RIGL: 3.40 (-0.05)
Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
PR Newswire - Tue Aug 30, 6:00AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, met the primary endpoint in the first of two double-blind studies in the FIT Phase 3 clinical program for the treatment of adult chronic/persistent immune thrombocytopenia (ITP). The study (n=76) showed that 18% of patients receiving fostamatinib achieved a stable platelet response compared to none receiving a placebo control (p=0.0261). A stable platelet response was defined as achieving greater than 50,000 platelets per uL of blood on at least four of the last six scheduled visits between weeks 14 and 24 of treatment. The results from the second FIT Phase 3 study are expected in October/November 2016.
RIGL: 3.40 (-0.05)
Rigel Announces Press Release and Conference Call Schedule on Tuesday, August 30, 2016
PR Newswire - Mon Aug 29, 4:34PM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) announced that the company will announce results of the first of two FIT Phase 3 studies of fostamatinib for patients with immune thrombocytopenia (ITP), at 7:00 a.m. Eastern Time (4:00 a.m. Pacific Time) on Tuesday, August 30, 2016. The company will also host a conference call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss the Phase 3 study results.
RIGL: 3.40 (-0.05)
Rigel Announces Second Quarter 2016 Financial Results and Provides Portfolio Update
PR Newswire - Tue Aug 02, 3:10PM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2016.
RIGL: 3.40 (-0.05)
Rigel to Present at Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9th at 10:30 am ET.
RIGL: 3.40 (-0.05)
Rigel to Present at Upcoming American Association of Immunologists (AAI) Annual Meeting
PR Newswire - Thu May 05, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present three scientific posters at the American Association of Immunologists (AAI) meeting in Seattle, Washington from May 13-17, 2016. The posters provide data from the company's preclinical research programs in key anti-inflammatory and autoimmune targets, Nrf2, MerTK and IRAK1/4. Rigel plans to partner select preclinical research programs in the future.
RIGL: 3.40 (-0.05)
Rigel Announces First Quarter 2016 Financial Results
PR Newswire - Tue May 03, 3:05PM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2016.
RIGL: 3.40 (-0.05)
Rigel Announces Conference Call and Webcast to Report First Quarter 2016 Financial Results
PR Newswire - Tue Apr 26, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2016 financial results after market close on Tuesday, May 3, 2016. Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results.
RIGL: 3.40 (-0.05)
Rigel Announces Presentations at Upcoming American Association of Cancer Research (AACR) Conference
PR Newswire - Tue Apr 12, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will present three scientific posters at the American Association of Cancer Research meeting in New Orleans, Louisiana from April 16 - 20, 2016. The posters will provide data from the company's preclinical research projects focused on the important oncology and immuno-oncology targets, IRAK, AMPK and MerTK. Rigel plans to partner select preclinical research programs in the future.
RIGL: 3.40 (-0.05)
Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP
PR Newswire - Fri Apr 01, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced it has completed enrollment for both studies in the FIT Phase 3 clinical program of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, in immune thromboycytopenic purpura (ITP). The first study in this program completed enrollment at the end of January and the second study has now completed enrollment. The results from the first study are expected in the middle of 2016, with the results for the second study expected shortly thereafter.
RIGL: 3.40 (-0.05)
Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT)
PR Newswire - Thu Jan 28, 6:30AM CST
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that the first of two Phase 3 clinical studies of fostamatinib in immune thrombocytopenic purpura (ITP) completed patient enrollment this month. The results from this first study are expected in the middle of 2016, with the results from the second study expected shortly thereafter.
RIGL: 3.40 (-0.05)
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutic Development Pipeline Review, H2 2015
M2 - Wed Jan 27, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8qf3c9/idiopathic) has announced the addition of the "Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview - Therapeutics Development - Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview - Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Comparative Analysis - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Development by Companies - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Investigation by Universities/Institutes - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Development by Companies - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Investigation by Universities/Institutes - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development - 3SBio Inc. - Amgen Inc. - Baxalta Incorporated - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Eisai Co., Ltd. - Hansa Medical AB - Immunomedics, Inc. - Intas Pharmaceuticals Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - Merck & Co., Inc. - Momenta Pharmaceuticals, Inc. - Novartis AG - Pfizer Inc. - PhytoHealth Corporation - Protalex, Inc. - Rigel Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/8qf3c9/idiopathic
IMMU: 2.74 (+0.06), PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36), BMY: 56.35 (-0.41), RIGL: 3.40 (-0.05), MNTA: 12.30 (+0.15), MRK: 62.98 (+0.08), BXLT: 46.02 (-0.18), NVS: 79.38 (+1.11)
Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
PR Newswire - Thu Jan 07, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present a review of products in development and a financial overview at the upcoming 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 14 at 9:30 a.m. Pacific Time (see webcast details below).
JPM: 67.49 (+0.28), RIGL: 3.40 (-0.05)
Bristol-Myers & UCLA Sign Immuno-Oncology Collaboration
Zacks Equity Research - Zacks Investment Research - Tue Dec 15, 3:25PM CST
Bristol-Myers Squibb Company (BMY) announced that it has entered into a collaboration agreement with UCLA under its Immuno-Oncology Rare Population Malignancy research program.
LLY: 76.85 (-0.38), BMY: 56.35 (-0.41), RIGL: 3.40 (-0.05), FPRX: 43.71 (-1.03)
A look at Equity Market Momentum - Research on Telecommunication Systems, Rigel Pharmaceuticals, Real Industry and Harmony Gold Mining Company
ACCESSWIRE - Wed Nov 18, 7:45AM CST
NEW YORK, NY / ACCESSWIRE / November 18, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Telecommunication Systems Inc (NASDAQ: TSYS), Rigel Pharmaceuticals Inc (NASDAQ: RIGL), Real Industry Inc (NASDAQ: RELY) and Harmony Gold Mining Company Ltd (NYSE: HMY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
TSYS: 4.99 (-0.02), RELY: 6.89 (+0.16), HMY: 4.02 (+0.10), RIGL: 3.40 (-0.05)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttwz6m/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Allergan Plc - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lee's Pharmaceutical Holdings Limited - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Nanomerics Ltd - Neuroptis Biotech - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Rigel Pharmaceuticals, Inc. - Samjin Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - TearSolutions, LLC. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/tt...njunctivit
VRTX: 95.11 (+0.36), RIGL: 3.40 (-0.05), OCUL: 6.38 (+0.02), AGN: 235.96 (-1.80), SHPG: 192.37 (+3.87), MRK: 62.98 (+0.08), CLTX: 36.01 (+16.34)
Rigel incurs lower net loss of USD6.7m in Q3 2015
M2 - Wed Nov 04, 4:11AM CST
Drug company Rigel Pharmaceuticals (NasdaqGS:RIGL) disclosed on Tuesday that it recorded a net loss of USD6.7m (USD0.08 per share) for the third quarter ended 30 September 2015.
RIGL: 3.40 (-0.05)
Rigel reports 3Q loss
Automated Insights - Tue Nov 03, 4:09PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported a loss of $6.7 million in its third quarter.
RIGL: 3.40 (-0.05)
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), MYL: 39.97 (-1.95), AMGN: 169.77 (-0.36), ARIA: 10.12 (-0.07), RIGL: 3.40 (-0.05), REGN: 388.64 (-4.76)
Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:16AM CDT
Rigel (RIGL) announced positive data from a phase III study on fostamatinib for the treatment of adult chronic/persistent ITP.
ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33), RIGL: 3.40 (-0.05)
Market Movers & Headline Makers On Tuesday
PR Newswire - Tue Aug 30, 10:17AM CDT
TechStockInsider.com Briefing: Despite the continued market confusion, stocks have remained in the center stage on Tuesday. The markets have been relatively quiet during these last few weeks of the summer and it has many traders confused. As one CNBC article states, "Stocks are just doing their own thing, which is why they've been so confusing for traders over the last few weeks." Despite this case, many companies are gaining attention for major milestones being hit prior to the start of the school season. Companies like Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), Life Clips, Inc. (OTCQB: LCLP), Skyline Medical Inc. (NASDAQ: SKLN), and Progressive Care, Inc. (OTC: RXMD) have all gained attention in the markets for their recent announcements.
SKLN: 0.18 (+0.02), RIGL: 3.40 (-0.05)
Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
PR Newswire - Tue Aug 30, 6:00AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, met the primary endpoint in the first of two double-blind studies in the FIT Phase 3 clinical program for the treatment of adult chronic/persistent immune thrombocytopenia (ITP). The study (n=76) showed that 18% of patients receiving fostamatinib achieved a stable platelet response compared to none receiving a placebo control (p=0.0261). A stable platelet response was defined as achieving greater than 50,000 platelets per uL of blood on at least four of the last six scheduled visits between weeks 14 and 24 of treatment. The results from the second FIT Phase 3 study are expected in October/November 2016.
RIGL: 3.40 (-0.05)
Rigel Announces Press Release and Conference Call Schedule on Tuesday, August 30, 2016
PR Newswire - Mon Aug 29, 4:34PM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) announced that the company will announce results of the first of two FIT Phase 3 studies of fostamatinib for patients with immune thrombocytopenia (ITP), at 7:00 a.m. Eastern Time (4:00 a.m. Pacific Time) on Tuesday, August 30, 2016. The company will also host a conference call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss the Phase 3 study results.
RIGL: 3.40 (-0.05)
Rigel Announces Second Quarter 2016 Financial Results and Provides Portfolio Update
PR Newswire - Tue Aug 02, 3:10PM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2016.
RIGL: 3.40 (-0.05)
Rigel to Present at Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9th at 10:30 am ET.
RIGL: 3.40 (-0.05)
Rigel to Present at Upcoming American Association of Immunologists (AAI) Annual Meeting
PR Newswire - Thu May 05, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present three scientific posters at the American Association of Immunologists (AAI) meeting in Seattle, Washington from May 13-17, 2016. The posters provide data from the company's preclinical research programs in key anti-inflammatory and autoimmune targets, Nrf2, MerTK and IRAK1/4. Rigel plans to partner select preclinical research programs in the future.
RIGL: 3.40 (-0.05)
Rigel Announces First Quarter 2016 Financial Results
PR Newswire - Tue May 03, 3:05PM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2016.
RIGL: 3.40 (-0.05)
Rigel Announces Conference Call and Webcast to Report First Quarter 2016 Financial Results
PR Newswire - Tue Apr 26, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2016 financial results after market close on Tuesday, May 3, 2016. Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results.
RIGL: 3.40 (-0.05)
Rigel Announces Presentations at Upcoming American Association of Cancer Research (AACR) Conference
PR Newswire - Tue Apr 12, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will present three scientific posters at the American Association of Cancer Research meeting in New Orleans, Louisiana from April 16 - 20, 2016. The posters will provide data from the company's preclinical research projects focused on the important oncology and immuno-oncology targets, IRAK, AMPK and MerTK. Rigel plans to partner select preclinical research programs in the future.
RIGL: 3.40 (-0.05)
Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP
PR Newswire - Fri Apr 01, 6:30AM CDT
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced it has completed enrollment for both studies in the FIT Phase 3 clinical program of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, in immune thromboycytopenic purpura (ITP). The first study in this program completed enrollment at the end of January and the second study has now completed enrollment. The results from the first study are expected in the middle of 2016, with the results for the second study expected shortly thereafter.
RIGL: 3.40 (-0.05)
Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT)
PR Newswire - Thu Jan 28, 6:30AM CST
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that the first of two Phase 3 clinical studies of fostamatinib in immune thrombocytopenic purpura (ITP) completed patient enrollment this month. The results from this first study are expected in the middle of 2016, with the results from the second study expected shortly thereafter.
RIGL: 3.40 (-0.05)
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutic Development Pipeline Review, H2 2015
M2 - Wed Jan 27, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8qf3c9/idiopathic) has announced the addition of the "Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview - Therapeutics Development - Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview - Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Comparative Analysis - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Development by Companies - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Investigation by Universities/Institutes - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Development by Companies - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Investigation by Universities/Institutes - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development - 3SBio Inc. - Amgen Inc. - Baxalta Incorporated - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Eisai Co., Ltd. - Hansa Medical AB - Immunomedics, Inc. - Intas Pharmaceuticals Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - Merck & Co., Inc. - Momenta Pharmaceuticals, Inc. - Novartis AG - Pfizer Inc. - PhytoHealth Corporation - Protalex, Inc. - Rigel Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/8qf3c9/idiopathic
IMMU: 2.74 (+0.06), PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36), BMY: 56.35 (-0.41), RIGL: 3.40 (-0.05), MNTA: 12.30 (+0.15), MRK: 62.98 (+0.08), BXLT: 46.02 (-0.18), NVS: 79.38 (+1.11)
Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
PR Newswire - Thu Jan 07, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present a review of products in development and a financial overview at the upcoming 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 14 at 9:30 a.m. Pacific Time (see webcast details below).
JPM: 67.49 (+0.28), RIGL: 3.40 (-0.05)
Bristol-Myers & UCLA Sign Immuno-Oncology Collaboration
Zacks Equity Research - Zacks Investment Research - Tue Dec 15, 3:25PM CST
Bristol-Myers Squibb Company (BMY) announced that it has entered into a collaboration agreement with UCLA under its Immuno-Oncology Rare Population Malignancy research program.
LLY: 76.85 (-0.38), BMY: 56.35 (-0.41), RIGL: 3.40 (-0.05), FPRX: 43.71 (-1.03)
A look at Equity Market Momentum - Research on Telecommunication Systems, Rigel Pharmaceuticals, Real Industry and Harmony Gold Mining Company
ACCESSWIRE - Wed Nov 18, 7:45AM CST
NEW YORK, NY / ACCESSWIRE / November 18, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Telecommunication Systems Inc (NASDAQ: TSYS), Rigel Pharmaceuticals Inc (NASDAQ: RIGL), Real Industry Inc (NASDAQ: RELY) and Harmony Gold Mining Company Ltd (NYSE: HMY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
TSYS: 4.99 (-0.02), RELY: 6.89 (+0.16), HMY: 4.02 (+0.10), RIGL: 3.40 (-0.05)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttwz6m/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Allergan Plc - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lee's Pharmaceutical Holdings Limited - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Nanomerics Ltd - Neuroptis Biotech - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Rigel Pharmaceuticals, Inc. - Samjin Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - TearSolutions, LLC. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/tt...njunctivit
VRTX: 95.11 (+0.36), RIGL: 3.40 (-0.05), OCUL: 6.38 (+0.02), AGN: 235.96 (-1.80), SHPG: 192.37 (+3.87), MRK: 62.98 (+0.08), CLTX: 36.01 (+16.34)
Rigel incurs lower net loss of USD6.7m in Q3 2015
M2 - Wed Nov 04, 4:11AM CST
Drug company Rigel Pharmaceuticals (NasdaqGS:RIGL) disclosed on Tuesday that it recorded a net loss of USD6.7m (USD0.08 per share) for the third quarter ended 30 September 2015.
RIGL: 3.40 (-0.05)
Rigel reports 3Q loss
Automated Insights - Tue Nov 03, 4:09PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported a loss of $6.7 million in its third quarter.
RIGL: 3.40 (-0.05)
